Article

Aberrant DNA Methylation of rDNA and PRIMA1 in Borderline Personality Disorder

Stefanie Teschler 1, Julia Gotthardt 1, Gerhard Dammann 2 and Reinhard H. Dammann 1,*

Received: 14 October 2015; Accepted: 29 December 2015; Published: 5 January 2016

Abstract: Borderline personality disorder (BPD) is a serious psychic disease with a high risk for suicide. DNA methylation is a hallmark for aberrant epigenetic regulation and could be involved in the etiology of BPD. Previously, it has been reported that increased DNA methylation of neuropsychiatric genes is found in the blood of patients with BPD compared to healthy controls. Here, we analyzed DNA methylation patterns of the ribosomal RNA gene (rDNA promoter region and 5′-external transcribed spacer/5′ETS) and the promoter of the proline rich membrane anchor 1 gene (PRIMA1) in peripheral blood samples of 24 female patients (mean age (33 ± 11) years) diagnosed with DSM-IV BPD and in 11 female controls (mean age (32 ± 7) years). A significant aberrant methylation of rDNA and PRIMA1 was revealed for BPD patients using pyrosequencing. For the promoter of PRIMA1, the average methylation of six CpG sites was 1.6-fold higher in BPD patients compared to controls. In contrast, the methylation levels of the rDNA promoter region and the 5′ETS were significantly lower (0.9-fold) in patients with BPD compared to controls. Thus, for nine CpGs located in the rDNA promoter region and for four CpGs at the 5′ETS decreased methylation was found in peripheral blood of patients compared to controls. Our results suggest that aberrant methylation of rDNA and PRIMA1 is associated with the pathogenesis of BPD.

Keywords: borderline personality disorder; ribosomal RNA gene; proline rich membrane anchor gene; epigenetics; DNA methylation

1. Introduction

Typical features of borderline personality disorder (BPD) are impulsive aggression, emotional dysregulation, repeated self-injury, but also chronic suicidality, and, therefore, BPD patients are often under clinical treatments [1,2]. Different signs of psychosocial impairment have been reported and the 50-times increased suicidality causes a 10% mortality rate in BPD patients [3]. Treatments like semi-structural interviews are of benefit for BPD patients [4]. BPD seems to be less stable over time than expected for personality disorders [5]. For the etiology of BPD, little is known; however, epigenetic and genetic factors [6–8] and physical and sexual abuse during childhood [9] have been associated with the pathogenesis of BPD.

Various forms of epigenetic regulation at the levels of DNA methylation, histone modification, and non-coding RNAs (ncRNAs) can modulate transcriptional and translational events required for memory processes [10]. About 60% of genes harbor CpG- and GC-rich DNA sequences in their 5′ regulatory region, which are termed CpG island promoters [11]. Active genes are associated with an open and unmethylated CpG island promoter and hypermethylated CpG islands are correlated...
with epigenetically silenced genes [12,13]. By changing the cellular profile in the brain's emotional, reward, and memory circuits, these epigenetic modifications have also been linked to perseverant, pathogenic memories typical for post-traumatic stress disorder (PTSD), major depressive disorder (MDD) and BPD [10,14]. Since environmental stimuli can influence epigenetic modifications, like DNA methylation, these aberrant marks could be associated with the development of anxiety [15], suicidality [16], and vulnerability for stress [17]. Previously, significant aberrant DNA methylation of serotonin receptor 2A (HTR2A), monoamine oxidase A and B (MAOA and MAOB), glucocorticoid receptor (NR3C1), brain derived neurotrophic factor (BDNF), amyloid beta precursor protein-binding family A member 2 and 3 (APBA2 and APBA3), KCNQ1, MCF2, and ninjurin 2 (NINJ2) has been reported [18–29]. Changes in DNA methylation range from 1.1- to 1.5-fold increased methylation in the blood of patients with BPD. Especially, NR3C1 methylation was positively associated with childhood maltreatment and clinical severity in BPD [22,23].

Recently, a genome-wide screen for DNA methylation has been performed for the major depressive disorder (MDD) [14]. Sabuncian et al. compared the methylation pattern of 39 postmortem frontal cortex MDD samples to 26 controls. They reported increased methylation (12%–15%) of the proline rich membrane anchor 1 gene (PRIMA1) and a concomitant decrease in gene expression [14]. PRIMA1 functions by organizing acetylcholinesterase into tetramers, and by anchoring these tetramers at neural cell membranes [30,31]. Increased methylation of PRIMA1 results in decreased enzyme function and increased cholinergic transmission, consistent with a role of the cholinergic circuit in different psychiatric disorders [14,32]. In BPD, the activation of the cholinergic system in peripheral blood cells of patients has been reported [33]. Epigenetic deregulation of rRNA genes by aberrant DNA methylation has been found in different human diseases, including cancer [13,34,35]. In psychiatric diseases, increased methylation of the regulatory CpG island promoter of rRNA genes has been reported in the brain of suicide persons and this has been correlated with reduced rRNA levels [36].

In our study, we investigated the methylation levels of the promoter region and 5’ETS of the ribosomal RNA genes and of the promoter of PRIMA1 in peripheral blood from female patients diagnosed with BPD and age matched control samples from female students without prior history of mental disorders. Since a promoter harbors the main regulatory sequences of the associated gene, we analyzed the level of DNA methylation of this region via bisulfite pyrosequencing. Here, we report that a significant aberrant promoter methylation of rDNA and PRIMA1 was observed in the blood of BPD patients compared to controls.

2. Results and Discussion

2.1. Hypomethylation of rDNA in Borderline Personality Disorder

Previously, an increased methylation throughout the rDNA CpG island promoter has been revealed in the brain of suicide persons [36]. Especially, borderline personality disorder (BPD) is associated with a 50-times increase in suicidal rate compared to the general population. Since we have already reported aberrant methylation of several genes in the blood of BPD patients [19,28], we aimed to reveal the methylation status of rDNA in peripheral blood of BPD patients. Human rDNA consists of hundreds of rDNA repeats of CpG-rich rRNA genes (Figure 1A). We analyzed the methylation of nine CpGs located in the distal promoter region and four CpGs in the 5’ external transcribed spacer (5’ETS) (Figure 1B,C). Data on methylation levels were obtained from blood samples of 11 female controls and 24 female patients with BPD (Table 1).

For the rDNA promoter region, methylation levels in patients ranged from 10% to 30% with following percentages for CpG1: 18.7%, CpG2: 22.4%, CpG3: 24.2%, CpG4: 15.3%, CpG5: 13.5%, CpG6: 17.0%, CpG7: 28.6%, CpG8: 23.3% and 16.7% for CpG9 (Figure 2B). In controls slightly higher methylation levels were observed for the analyzed CpGs: 20.1% at CpG1; CpG2: 24.4%; CpG3: 24.3%; CpG4: 18.4%; CpG5: 15.2%; CpG6: 19.3%; CpG7: 29.9%; CpG8: 25.8% and CpG9: 18.3% (Figure 2B).
Table 1. Summarized data of the analyzed patients with BPD and control persons.

| Category                              | BPD Patients (n = 24) | Control Persons (n = 11) |
|---------------------------------------|-----------------------|--------------------------|
| Female                                | 24                    | 11                       |
| Mean age (±SD)                        | 33 ± 11               | 32 ± 7                   |
| DSM-IV criteria 1                     | 75% (18/24)           | 0% (p < 0.001)           |
| DSM-IV criteria 2                     | 54% (13/24)           | 0% (p < 0.003)           |
| DSM-IV criteria 3                     | 92% (22/24)           | 0% (p < 0.001)           |
| DSM-IV criteria 4                     | 63% (15/24)           | 0% (p < 0.001)           |
| DSM-IV criteria 5                     | 88% (21/24)           | 0% (p < 0.001)           |
| DSM-IV criteria 6                     | 88% (21/24)           | 0% (p < 0.001)           |
| DSM-IV criteria 7                     | 58% (14/24)           | 0% (p < 0.002)           |
| DSM-IV criteria 8                     | 63% (15/24)           | 0% (p < 0.001)           |
| DSM-IV criteria 9                     | 54% (13/24)           | 0% (p < 0.003)           |
| Observed positive diagnosis           | 100% (24/24)          | 0% (p < 0.001)           |
| Acute self injuring behavior (ASIB)   | 63% (15/24)           | 0% (p < 0.002)           |
| Prior self injuring behavior (PSIB)   | 88% (21/24)           | 0% (p < 0.001)           |
| Suicide background (SB)               | 83% (20/24)           | 0% (p < 0.001)           |
| Nicotine consumption (NC)             | 71% (17/24)           | 36% (4/11) (n.s.)        |
| Alcohol abuse (AA)                    | 25% (6/24)            | 0% (n.s.)                |
| Additional drug abuse (ADA)           | 17% (4/24)            | 0% (n.s.)                |
| Prior traumatic experience (PTE)      | 63% (15/24)           | 0% (p < 0.001)           |

* More details are listed in Table 2 and [19].  b DSM-IV: A pervasive pattern of instability of interpersonal relationships, self-image, and affects, and marked impulsivity beginning by early adulthood and present in a variety of contexts, as indicated by five (or more) of the following: criteria (crit.) 1: frantic efforts to avoid real or imagined abandonment. Note 1: Do not include suicidal or self-mutilating behavior covered in crit. 5; crit. 2: a pattern of unstable and intense interpersonal relationships characterized by alternating between extremes of idealization and devaluation; crit. 3: identity disturbance: markedly and persistently unstable self image or sense of self; crit. 4: impulsivity in at least two areas that are potentially self-damaging (e.g., spending, sex, substance abuse, reckless driving, binge eating); Note 2: Do not include suicidal or self-mutilating behavior covered in crit. 5; crit. 5: recurrent suicidal behavior, gestures, or threats, or self-mutilating behavior; crit. 6: affective instability due to a marked reactivity of mood (e.g., intense episodic dysphoria, irritability, or anxiety usually lasting a few hours and only rarely more than a few days); crit. 7: chronic feelings of emptiness; crit. 8: inappropriate, intense anger or difficulty controlling anger (e.g., frequent displays of temper, constant anger, recurrent physical fights); crit. 9: transient, stress-related paranoid ideation or severe dissociative symptoms; c two tailed Fisher exact probability test: n.s. not significant (p > 0.05).

Similarly, 5′ETS methylation levels of four CpG sites ranged from 10% to 30% in patients and controls (Figure 1C). Also here, in BPD patients a slightly lower level of methylation was found for all analyzed CpGs compared to controls (CpG1: 29.6% and 31.0%, CpG2: 11.3% and 11.8%, CpG3: 26.9% and 27.7%, CpG4: 22.9% and 23.5% (Figure 1C)). Interestingly, the mean methylation level was lower for all analyzed CpGs in the distal promoter region and 5′ETS in BPD patients (20% and 23%) compared to control patients (22% and 24%, respectively; Figure 1). However, due to inter- and intra-individual variations in rDNA methylation, a large variability was observed in peripheral blood. Utilizing a paired t-test analysis of the mean methylation of nine CpGs in the distal promoter, a significant decrease was detected in BPD samples compared to controls (Figure 2). For the promoter, a 0.92-fold lower methylation in BPD patients compared to controls was revealed (p < 0.001). In the 5′ETS, a similar trend (p = 0.02) with a 0.96-fold lower methylation level in BPD patients was observed (Figure 2). Thus, for both regions together, an average 0.93-fold lower methylation was found (p < 0.001; Figure 2).
Previously, aberrant DNA methylation of rRNA genes has been reported for different human diseases, including dementia [34,35]. For psychiatric diseases, rDNA was significantly higher
methylated throughout the promoter and 5' regulatory region in the brain of suicide subjects, consistent with reduced rRNA expression in the hippocampus [36]. In our study, however, we observed a hypomethylation of the distal rDNA promoter and 5'ETS region. This difference could be attributed to the analyzed regions or to distinct tissues analyzed. For example, in hepatocellular carcinoma, hypomethylation of the rDNA promoter has been revealed [37]. In other cancer tissues (e.g., breast, lung, colorectal and endometrial) hypermethylation of rRNA genes compared to normal tissues has been observed [13,34,38–40]. Thus, it will also be interesting to analyze the brain-specific methylation of rDNA in BPD patients. Bacalini et al. reported a considerable inter-individual variation in methylation levels [38], which was also seen in the blood of BPD patients and control samples. Therefore, a considerable standard deviation was observed. In eukaryotes, only a subset of rDNA is actively transcribed and the other fraction of repeats is epigenetically silenced [41–43]. We and others have shown that the inactive copies are packed into nucleosomes and contain methylated promoter sequences [44–46], whereas the transcribed rRNA genes are free of nucleosomes and the rRNA promoter is unmethylated [46–48]. Therefore, our data as well as other data suggest that, on average, 70% to 90% of the human rDNA repeats are epigenetically inactive [13,38].

2.2. Hypermethylation of PRIMA1 in Borderline Personality Disorder

In a genome-wide DNA methylation scan, increased methylation and a decreased gene expression of the proline rich membrane anchor 1 gene (PRIMA1) have been reported in the major depressive disorder (MDD) [14]. Thus, we aimed to reveal the methylation status of PRIMA1 in BPD. The promoter of PRIMA1 consists of one CpG island. We analyzed six CpGs upstream of the transcription initiation site by bisulfite pyrosequencing (Figure 3A). For BPD patients, methylation levels were as following: for CpG1 6.1%, CpG2: 5.4%, CpG3: 4.3%, CpG4: 3.8%, CpG5: 6.5% and 4.2% for CpG6 (Figure 3B). Due to inter-individual variations a large variability was observed. In controls lower methylation levels of PRIMA1 at all analyzed CpGs were observed (3.5% at CpG1; CpG2: 3.1%; CpG3: 2.7%; CpG4: 4.6%; CpG5 and CpG6: 3.0% (Figure 3B)). Thus, the mean methylation is 1.6-fold higher in BPD patients (5.1%) compared to controls (3.2%) (Figure 3B,C). Since the increased methylation was present at all six CpG sites (1.4- to 1.7-fold increase), this trend was significant in a statistical analysis with a paired t-test by dissecting the mean methylation of the six CpGs (p < 0.001; Figure 3C). The low methylation level of the PRIMA1 promoter is consistent with its localization in a CpG island region which in turn are rather unmethylated in tissues [11]. We and others have revealed low methylation levels (<10% methylation) at the CpG islands of the serotonin receptor 2A (HTR2A), glucocorticoid receptor (NR3C1) and brain derived neurotrophic factor (BDNF) [19,26,29].

In the major depressive disorder (MDD), an increased methylation of PRIMA1 was previously reported [14]. Sabunciy an et al. compared the methylation pattern of postmortem frontal cortex MDD samples to controls. Hereby, they revealed an increased methylation (1.2-fold) at six CpGs within the coding region of PRIMA1 [14]. Here, we detected an increased methylation (1.6-fold) in the proximal promoter region (Figure 3). Since only two patients (8%) had comorbid major depressive disorder (Table 2: F33.1), but all patients (100%) were positively diagnosed for BPD (Table 1), the observed difference in the methylation level cannot simply be attributed to comorbidity. Transcriptional regulation of PRIMA1 has been linked to the MAP kinase pathway [49]. The gene product of PRIMA1 functions by organizing acetylcholinesterase (AChE) into tetramers, and by anchoring AChE at membranes of neural cells [50–52]. The membrane-bound form of AChE is the major fraction in the mammalian brain [30]. AChE is a serine protease, which hydrolyses the neurotransmitter acetylcholine into acetate and choline, thereby terminating neurotransmission [53]. PRIMA1 is of substantial biological interest in psychiatric disorders because of its relationship to neurotransmission. Interestingly, when BPD patients were treated with physostigmine in order to analyze AChE system responsiveness, the depressive response to physostigmine was enhanced in BPD patients [54]. Physostigmine is a reversible inhibitor of AChE [53]. Thus, it will be interesting to analyze the levels of membrane bound AChE and PRIMA1 in the brains of BPD patients.
Figure 3. Methylation analysis of PRIMA1 in blood samples of borderline personality disorder patients and control persons. (A) Map of the PRIMA1 gene. Individual CpGs are indicated by vertical lines and the six analyzed CpGs are numbered. Primers are marked with arrows. For details also see Figure 1; (B) Methylation levels of six CpGs located in the proximal promoter region were obtained by bisulfite pyrosequencing. All CpGs indicate the mean methylation of the analyzed region; (C) The quotients between mean methylation levels at individual CpG sites and the sites combined for PRIMA1 in patients and controls (ctrls) were calculated and plotted. Statistical analysis was performed with the two-tailed, paired t-test comparing the mean methylation of matching CpG sites in a specific region.

3. Experimental Section

3.1. Tissue Samples

Whole blood samples of 24 female BPD patients and 11 age matched female controls were obtained from the Psychiatric Hospital in Münsterlingen, Switzerland (Tables 1 and 2) and are the same samples as previously described and utilized [19,28]. Diagnosis of BPD was established by an experienced psychiatrist (Gerhard Dammann) following SCID-II-Interview [55] for DSM-IV [56] diagnosis of personality disorders. All patients were diagnosed positively for BPD due to impulsivity, suicidality and depression found in patients (Table 1).

All patients were taking medications (mainly antidepressants and atypical antipsychotics). Due to ethical reasons it was not possible to stop medication. The normal control groups consisted of students without prior history of mental disorders [19,28]. Informed consent was obtained from all subjects. All experiments were performed in accordance with relevant guidelines and regulations. This study and all experiments were approved of by the local ethic committees: ethic committee of the Kanton Thurgau/CH, ethic committee of the University Halle/Germany and ethic committee of the Justus-Liebig University Giessen/Germany.
Table 2. Clinopathological parameters of borderline personality disorder (BPD) patients.

| Patient No. | Age | Crit. 1 | Crit. 2 | Crit. 3 | Crit. 4 | Crit. 5 | Crit. 6 | Crit. 7 | Crit. 8 | ASIB \(^a\) | PSIB \(^a\) | SB \(^a\) | NC \(^a\) | AA \(^a\) | ADA \(^a\) | PTE \(^a\) | Co-Diagnosis \(^a\) |
|-------------|-----|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|----------|----------------|
| 1           | 40  | +       | –       | +       | +       | +       | +       | –       | –       | +       | +       | +       | –       | –       | –       | –       | +        | –         |
| 2           | 33  | +       | –       | +       | +       | +       | +       | +       | +       | –       | –       | +       | +       | –       | –       | –       | –        | –         |
| 3           | 24  | +       | +       | +       | +       | +       | +       | –       | –       | +       | +       | +       | –       | –       | –       | –       | +        | –         |
| 4           | 40  | +       | –       | +       | –       | +       | +       | +       | –       | +       | +       | –       | –       | –       | –       | –       | –        | –         |
| 5           | 52  | +       | –       | +       | +       | –       | +       | –       | –       | +       | –       | –       | –       | –       | –       | –       | +        | –         |
| 6           | 17  | +       | +       | +       | +       | +       | +       | +       | +       | –       | –       | –       | +       | –       | –       | –       | –        | –         |
| 7           | 28  | +       | –       | +       | +       | –       | +       | +       | +       | –       | –       | –       | –       | –       | –       | –       | +        | F42.2     |
| 8           | 47  | +       | –       | +       | –       | +       | –       | –       | +       | –       | –       | –       | –       | –       | –       | –       | –        | –         |
| 9           | 51  | +       | –       | +       | –       | +       | –       | –       | +       | –       | –       | –       | –       | –       | –       | –       | –        | –         |
| 10          | 33  | +       | –       | +       | +       | –       | +       | +       | –       | +       | +       | +       | –       | –       | –       | –       | canabis   | –         |
| 11          | 18  | +       | –       | +       | +       | –       | –       | –       | +       | +       | –       | –       | –       | –       | –       | –       | –        | –         |
| 12          | 26  | +       | +       | +       | +       | –       | –       | +       | +       | +       | +       | –       | –       | –       | –       | –       | –        | –         |
| 13          | 24  | +       | +       | –       | –       | +       | +       | –       | +       | +       | +       | –       | –       | –       | –       | –       | –        | –         |
| 14          | 15  | –       | –       | –       | +       | +       | +       | –       | –       | –       | +       | +       | +       | +       | +       | +       | Ternest+  | –         |
| 15          | 23  | +       | +       | –       | +       | –       | –       | +       | +       | +       | +       | +       | +       | +       | +       | –       | +        | –         |
| 16          | 24  | +       | +       | –       | +       | +       | –       | –       | +       | +       | +       | +       | +       | +       | +       | +       | +        | –         |
| 17          | 45  | +       | +       | –       | –       | +       | +       | –       | –       | –       | –       | –       | –       | –       | –       | –       | –        | –         |
| 18          | 22  | –       | +       | +       | +       | –       | –       | +       | +       | +       | +       | +       | +       | +       | +       | +       | –        | –         |
| 19          | 36  | +       | +       | –       | +       | +       | +       | –       | +       | +       | +       | +       | +       | +       | +       | +       | +        | –         |
| 20          | 22  | +       | +       | –       | +       | +       | –       | +       | +       | +       | +       | +       | +       | +       | +       | +       | F33.1    | –         |
| 21          | 24  | +       | +       | +       | +       | +       | –       | +       | +       | –       | –       | –       | –       | –       | –       | –       | –        | –         |
| 22          | 25  | +       | +       | –       | +       | +       | –       | +       | +       | –       | –       | –       | –       | –       | –       | –       | –        | –         |
| 23          | 26  | +       | +       | –       | +       | +       | –       | +       | +       | –       | –       | –       | –       | –       | –       | –       | –        | –         |

\(^a\) ASIB: acute self injurying behavior; PSIB: prior self abusive behavior; SB: suicidal background; NC: nicotine consumption; AA: alcohol abuse; ADA: additional drug abuse; PTE: prior traumatic experiences; F10: mental and behavioral disorder due to alcoholism; F42.2: compulsive minds and acts, mixed; F19: psychic and behavioral disorder due to frequent substance abuse and consumption of additional psychotropic substances; F60.30: emotionally instable personality disorder: impulsive type; F33.1: recurrent depressive disorder, actual moderately episode; F10.21: psychic and behavioral disorder due to abuse of psychotropic substances; dependence syndrome; Z56: problems related to employment and unemployment; Z59: problems related to housing and economic circumstances; Z63: other problems related to primary support group, including family circumstances.
3.2. Methylation Analysis

DNA methylation levels of two rDNA regions (promoter and 5′ETS) and of PRIMA1 were determined by bisulfite pyrosequencing [13,19,57]. Bisulfite treatment of genomic DNA was done as described previously [19]. Bisulfite treatment was carried out with the EpiTect Kit (Qiagen, Hilden, Germany) according to the manufacture’s protocol. For pyrosequencing 100 ng of bisulfite treated DNA was amplified in a reaction buffer containing 0.2 mM dNTP mix, 1.5 mM MgCl₂ and 1.5 U Taq polymerase for 40 cycles with 10 pmol of each forward and biotinylated reverse primer and sequenced with an internal primer (Table 3). Pyrosequencing was performed in PyroMark Q24 according to the PyroMark Gold Q24 Reagents Handbook (Qiagen, Hilden, Germany). Pyrosequencing was performed in two to three independent bisulfite reactions and the average methylation frequency for each CpG site and rDNA region was calculated.

Table 3. Primers.

| Primer          | Sequence (5′–3′)         | Region                |
|-----------------|-------------------------|-----------------------|
| PROL            | GTTTTTYGTTGTTAGTAGGTAGTTTT | rDNA promoter         |
| PROF/PROFBIO    | AAAAAAAACRTCCCAACCTCC   | rDNA promoter         |
| PROSEQ          | GTTTATGGGGGAGGTTGTG      | rDNA promoter         |
| FETS            | GTAGGGTTTTTTTTTTTTTAGGTTTT | 5′ETS                 |
| LETS            | CTAAAAAAAACCTTTCTCAACcAAAAATAAA | 5′ETS               |
| PRIMABSU        | GGTTGGTTTTAATGGGGTTT    | PRIMA1                |
| PRIMABIO3       | ACCTCATTACRCACACTACAACATAAA | PRIMA1                |

3.3. Statistical Evaluation

Statistical analyses were performed using Excel (Microsoft, Redmond, WA, USA). All reported p-values are considered significant for \( p \leq 0.05 \).

4. Conclusions

The present study is the first comparative analysis of DNA methylation of rDNA and PRIMA1 in borderline personality disorder (BPD). In summary, we were able to show a significantly increased methylation of the PRIMA1 promoter in peripheral blood samples of patients with BPD compared to controls. Interestingly, a decrease in the methylation level of the distal promoter and 5′ETS region of rDNA was revealed in the BPD patients. However, the small and unequal sample size and liberal p-value limit the interpretation of the data. Thus, it will be interesting to extend analysis to a larger set of patients and to elucidate whether significant correlations between methylation levels and clinical parameters are present. Additionally, it will be fascinating to study the factors involved in the alteration in the pathway of DNA methylation during the pathogenesis of BPD.

Acknowledgments: Research in Reinhard Dammann’s laboratory is funded by Land Hessen (LOEWE) and Deutsche Forschungsgemeinschaft (TRR81). These organizations had neither an involvement in the study design, acquisition, analysis, data interpretation, and writing of the manuscript nor in the decision to submit the manuscript for publication. We thank Michelle Woods for proofreading the manuscript.

Author Contributions: Reinhard H. Dammann has created this study. Stefanie Teschler and Reinhard H. Dammann participated in the design of the study. Stefanie Teschler, Julia Gotthardt and Gerhard Dammann acquired data. Stefanie Teschler, Julia Gotthardt; Gerhard Dammann and Reinhard H. Dammann controlled analyzed and interpreted data. Reinhard H. Dammann prepared the manuscript. Stefanie Teschler, Julia Gotthardt, Gerhard Dammann and Reinhard H. Dammann read, corrected and approved the final manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Leichsenring, F.; Leibing, E.; Kruse, J.; New, A.S.; Leweke, F. Borderline personality disorder. *Lancet* 2011, **377**, 74–84. [CrossRef]
2. Lieb, K.; Zanarini, M.C.; Schmahl, C.; Linehan, M.M.; Bohus, M. Borderline personality disorder. *Lancet* 2004, 364, 453–461. [CrossRef]

3. Skodol, A.E.; Gunderson, J.G.; McGlashan, T.H.; Dyck, I.R.; Stout, R.L.; Bender, D.S.; Grilo, C.M.; Shea, M.T.; Zanarini, M.C.; Morey, L.C.; *et al.* Functional impairment in patients with schizotypal, borderline, avoidant, or obsessive-compulsive personality disorder. *Am. J. Psychiatry* 2002, 159, 276–283. [CrossRef] [PubMed]

4. Zimmerman, M. Diagnosing personality disorders. A review of issues and research methods. *Arch. Gen. Psychiatry* 1994, 51, 225–245. [CrossRef] [PubMed]

5. Zanarini, M.C.; Frankenburg, F.R.; Hennen, J.; Reich, D.B.; Silk, K.R. Prediction of the 10-year course of borderline personality disorder. *Am. J. Psychiatry* 2006, 163, 827–832. [CrossRef] [PubMed]

6. Siever, L.J.; Torgersen, S.; Gunderson, J.G.; Livesley, W.J.; Kendler, K.S. The borderline diagnosis III: Identifying endophenotypes for genetic studies. *Biol. Psychiatry* 2002, 51, 964–968. [CrossRef]

7. Skodol, A.E.; Siever, L.J.; Livesley, W.J.; Gunderson, J.G.; Pfahl, B.; Widiger, T.A. The borderline diagnosis II: Biology, genetics, and clinical course. *Biol. Psychiatry* 2002, 51, 951–963. [CrossRef]

8. Torgersen, S.; Czajkowski, N.; Jacobson, K.; Reichborn-Kjennerud, T.; Roysamb, E.; Neale, M.C.; Kendler, K.S. Dimensional representations of DSM-IV cluster B personality disorders in a population-based sample of norwegian twins: A multivariate study. *Psychol. Med.* 2008, 38, 1617–1625. [CrossRef] [PubMed]

9. Soloff, P.H.; Lynch, K.G.; Kelly, T.M. Childhood abuse as a risk factor for suicidal behavior in borderline personality disorder. *J. Pers. Disord.* 2002, 16, 201–214. [CrossRef] [PubMed]

10. Sillivan, S.E.; Vaissiere, T.; Miller, C.A. Neuroepigenetic regulation of pathogenic memories. *Neuroepigenetics* 2015, 1, 28–33. [CrossRef] [PubMed]

11. Bird, A.P. CpG-rich islands and the function of DNA methylation. *Nature* 1986, 321, 209–213. [CrossRef] [PubMed]

12. Dammann, R.; Li, C.; Yoon, J.H.; Chin, P.L.; Bates, S.; Pfeifer, G.P. Epigenetic inactivation of a ras association domain family protein from the lung tumour suppressor locus 3p21.3. *Nat. Genet.* 2000, 25, 315–319. [PubMed]

13. Teschler, S.; Richter, A.; Linder, B.; Dammann, R. Aberrant DNA methylation of ribosomal RNA genes in human cancer. *Mol. Biol.* 2015, 4, 2. [PubMed]

14. Sabunciyan, S.; Aryee, M.J.; Irizarry, R.A.; Rongione, M.; Webster, M.J.; Kaufman, W.E.; Murakami, P.; Lessard, A.; Yolken, R.H.; Feinberg, A.P.; *et al.* Genome-wide DNA methylation scan in major depressive disorder. *PLoS ONE* 2012, 7, e34451. [CrossRef] [PubMed]

15. Alisch, R.S.; Chopra, P.; Fox, A.S.; Chen, K.; White, A.T.; Roseboom, P.H.; Keles, S.; Kalin, N.H. Differentially methylated plasticity genes in the amygdala of young primates are linked to anxious temperament, an at risk phenotype for anxiety and depressive disorders. *J. Neurosci.* 2014, 34, 15548–15556. [CrossRef] [PubMed]

16. Turecki, G. The molecular bases of the suicidal brain. *Nat. Rev. Neurosci.* 2014, 15, 802–816. [CrossRef] [PubMed]

17. Tsuji, M.; Miyagawa, K.; Takeda, H. Epigenetic regulation of resistance to emotional stress: Possible involvement of 5-HT1A receptor-mediated histone acetylation. *J. Pharm. Sci.* 2014, 125, 347–354. [CrossRef]

18. Carrard, A.; Salzmann, A.; Malafosse, A.; Karege, F. Increased DNA methylation status of the serotonin receptor 5HT1A gene promoter in schizophrenia and bipolar disorder. *J. Affect. Disord.* 2011, 132, 450–453. [CrossRef] [PubMed]

19. Dammann, G.; Teschler, S.; Haag, T.; Altmuller, F.; Tuzek, F.; Dammann, R.H. Increased DNA methylation of neuropsychiatric genes occurs in borderline personality disorder. *Epigenetics* 2011, 6, 1454–1462. [CrossRef] [PubMed]

20. Groleau, P.; Joober, R.; Israel, M.; Zeramondini, N.; DeGuzman, R.; Steiger, H. Methylation of the dopamine D2 receptor (DRD2) gene promoter in women with a bulimia-spectrum disorder: Associations with borderline personality disorder and exposure to childhood abuse. *J. Psychiatr. Res.* 2014, 48, 121–127. [CrossRef] [PubMed]

21. Grosjean, B.; Tsai, G.E. Nmda neurotransmission as a critical mediator of borderline personality disorder. *J. Psychiatry Neurosci.* 2007, 32, 103–115. [PubMed]

22. Martin-Blanco, A.; Ferrer, M.; Soler, J.; Salazar, J.; Vega, D.; Andion, O.; Sanchez-Mora, C.; Arranz, M.J.; Ribases, M.; Feliu-Soler, A.; *et al.* Association between methylation of the glucocorticoid receptor gene, childhood maltreatment, and clinical severity in borderline personality disorder. *J. Psychiatr. Res.* 2014, 57, 34–40. [CrossRef] [PubMed]
23. Perroud, N.; Paoloni-Giacobino, A.; Prada, P.; Olie, E.; Salzmann, A.; Nicastro, R.; Guillaume, S.; Mouthon, D.; Stoud, C.; Dieben, K.; et al. Increased methylation of glucocorticoid receptor gene (NR3C1) in adults with a history of childhood maltreatment: A link with the severity and type of trauma. *Transl. Psychiatry* 2011, 1, e59. [CrossRef] [PubMed]

24. Perroud, N.; Salzmann, A.; Prada, P.; Nicastro, R.; Hoeppli, M.E.; Furrer, S.; Ardu, S.; Krejci, I.; Karege, F.; Malafosse, A. Response to psychotherapy in borderline personality disorder and methylation status of the bdnf gene. *Transl. Psychiatry* 2013, 3, e207. [CrossRef] [PubMed]

25. Prados, J.; Stenz, L.; Courtet, P.; Prada, P.; Nicastro, R.; Adouan, W.; Guillaume, S.; Olie, E.; Aubry, J.M.; Dayer, A.; et al. Borderline personality disorder and childhood maltreatment: A genome-wide methylation analysis. *Genes Brain Behav.* 2015, 14, 177–188. [CrossRef] [PubMed]

26. Steiger, H.; Labonte, B.; Groleau, P.; Turecki, G.; Israel, M. Methylation of the glucocorticoid receptor gene promoter in bulimic women: Associations with borderline personality disorder, suicidality, and exposure to childhood abuse. *Int. J. Eating Disorder.* 2013, 46, 246–255. [CrossRef] [PubMed]

27. Tadic, A.; Elsasser, A.; Victor, A.; von Cube, R.; Baskaya, O.; Wagner, S.; Lieb, K.; Hoppner, W.; Dahmen, N. Association analysis of serotonin receptor 1B (HTR1B) and brain-derived neurotrophic factor gene polymorphisms in borderline personality disorder. *J. Neural Transm.* 2009, 116, 1185–1188. [CrossRef] [PubMed]

28. Teschler, S.; Bartkuhn, M.; Kunzel, N.; Schmidt, C.; Kiehl, S.; Dammann, G.; Dammann, R. Aberrant methylation of gene associated CpG sites occurs in borderline personality disorder. *PLoS ONE* 2013, 8, e84180. [CrossRef] [PubMed]

29. Thaler, L.; Gauvin, L.; Joober, R.; Groleau, P.; de Guzman, R.; Ambalavanan, A.; Israel, M.; Wilson, S.; Steiger, H. Methylation of bdnf in women with bulimic eating syndromes: Associations with childhood abuse and borderline personality disorder. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* 2014, 54, 43–49. [CrossRef] [PubMed]

30. Massoulie, J. The origin of the molecular diversity and functional anchoring of cholinesterases. *Neuro-Signals* 2002, 11, 130–143. [CrossRef] [PubMed]

31. Noureddine, H.; Schmitt, C.; Liu, W.; Garbay, C.; Massoulie, J.; Bon, S. Assembly of acetylcholinesterase tetramers by peptidic motifs from the proline-rich membrane anchor, prima: Competition between degradation and secretion pathways of heteromeric complexes. *J. Biol. Chem.* 2007, 282, 3487–3497. [CrossRef] [PubMed]

32. Siever, L.J.; Weinstein, L.N. The neurobiology of personality disorders: Implications for psychoanalysis. *J. Am. Psychoanal. Assoc.* 2009, 57, 361–398. [CrossRef] [PubMed]

33. Diaz-Marsa, M.; Macdowell, K.S.; Guemes, I.; Rubio, V.; Carrasco, J.L.; Leza, J.C. Activation of the cholinergic anti-inflammatory system in peripheral blood mononuclear cells from patients with borderline personality disorder. *J. Psychiatr. Res.* 2012, 46, 1610–1617. [CrossRef] [PubMed]

34. Powell, M.A.; Mutch, D.G.; Rader, J.S.; Herzog, T.J.; Huang, T.H.; Goodfellow, P.J. Ribosomal DNA methylation in patients with endometrial carcinoma: An independent prognostic marker. *Cancer* 2002, 94, 2941–2952. [CrossRef] [PubMed]

35. Pietrzak, M.; Rempala, G.; Nelson, P.T.; Zheng, J.J.; Hetman, M. Epigenetic silencing of nucleolar rRNA genes in Alzheimer’s disease. *PLoS ONE* 2011, 6, e22585. [CrossRef] [PubMed]

36. McGowan, P.O.; Sasaki, A.; Huang, T.C.; Unterberger, A.; Suderman, M.; Ernst, C.; Meaney, M.J.; Turecki, G.; Szyf, M. Promoter-wide hypermethylation of the ribosomal RNA gene promoter in the suicide brain. *PLoS ONE* 2008, 3, e2085. [CrossRef] [PubMed]

37. Ghoshal, K.; Majumder, S.; Datta, J.; Motiwala, T.; Bai, S.; Sharma, S.M.; Frankel, W.; Jacob, S.T. Role of human ribosomal RNA (rRNA) promoter methylation and of methyl-CpG-binding protein MB2 in the suppression of rRNA gene expression. *J. Biol. Chem.* 2004, 279, 6783–6793. [CrossRef] [PubMed]

38. Bacalini, M.G.; Pacilli, A.; Giuliani, C.; Penzo, M.; Trere, D.; Pirazzini, C.; Salvioli, S.; Franceschi, C.; Montanaro, L.; Garagnani, P. The nucleolar size is associated to the methylation status of ribosomal DNA in breast carcinomas. *BMC Cancer* 2014, 14, 361. [CrossRef] [PubMed]

39. Toyota, M.; Ho, C.; Ahuja, N.; Jair, K.W.; Li, Q.; Ohe-Toyoda, M.; Baylin, S.B.; Issa, J.P. Identification of differentially methylated sequences in colorectal cancer by methylated cpg island amplification. *Cancer Res.* 1999, 59, 2307–2312. [PubMed]
40. Yan, P.S.; Rodriguez, F.J.; Laux, D.E.; Perry, M.R.; Standiford, S.B.; Huang, T.H. Hypermethylation of ribosomal DNA in human breast carcinoma. Br. J. Cancer 2000, 82, 514–517. [CrossRef] [PubMed]

41. Conconi, A.; Widmer, R.M.; Koller, T.; Sogo, J.M. Two different chromatin structures coexist in ribosomal RNA genes throughout the cell cycle. Cell 1989, 57, 753–761. [CrossRef]

42. Grummt, I.; Langst, G. Epigenetic control of RNA polymerase i transcription in mammalian cells. Biochim. Biophys. Acta 2013, 1829, 393–404. [CrossRef] [PubMed]

43. Preuss, S.; Pikaard, C.S. rRNA gene silencing and nucleolar dominance: Insights into a chromosome-scale epigenetic on/off switch. Biochim. Biophys. Acta 2007, 1769, 383–392. [CrossRef] [PubMed]

44. Dammann, R.; Lucchini, R.; Koller, T.; Sogo, J.M. Transcription in the yeast rRNA gene locus: Distribution of the active gene copies and chromatin structure of their flanking regulatory sequences. Mol. Cell. Biol. 1995, 15, 5294–5303. [CrossRef] [PubMed]

45. Stancheva, I.; Lucchini, R.; Koller, T.; Sogo, J.M. Chromatin structure and methylation of rat rRNA genes studied by formaldehyde fixation and psoralen cross-linking. Nucleic Acids Res. 1997, 25, 1727–1735. [CrossRef] [PubMed]

46. Santoro, R.; Grummt, I. Molecular mechanisms mediating methylation-dependent silencing of ribosomal gene transcription. Mol. Cell 2001, 8, 719–725. [CrossRef]

47. Dammann, R.; Lucchini, R.; Koller, T.; Sogo, J.M. Chromatin structures and transcription of rDNA in yeast saccharomyces cerevisiae. Nucleic Acids Res. 1993, 21, 2331–2338. [CrossRef] [PubMed]

48. Zentner, G.E.; Saiakhova, A.; Manaenkov, P.; Adams, M.D.; Scacheri, P.C. Integrative genomic analysis of human ribosomal DNA. Nucleic Acids Res. 2011, 39, 4949–4960. [CrossRef] [PubMed]

49. Xie, H.Q.; Choi, R.C.; Leung, K.W.; Chen, V.P.; Chu, G.K.; Tsim, K.W. Transcriptional regulation of proline-rich membrane anchor (PRIMA) of globular form acetylcholinesterase in neuron: An inductive effect of neuron differentiation. Brain Res. 2009, 1265, 13–23. [CrossRef] [PubMed]

50. Perrier, N.A.; Kherif, S.; Perrier, A.L.; Dumas, S.; Mallet, J.; Massoulie, J. Expression of prima in the mouse brain: Membrane anchoring and accumulation of 'tailed' acetylcholinesterase. Eur. J. Neurosci. 2003, 18, 1837–1847. [CrossRef] [PubMed]

51. Xie, H.Q.; Liang, D.; Leung, K.W.; Chen, V.P.; Zhu, K.Y.; Chan, W.K.; Choi, R.C.; Massouille, J.; Tsim, K.W. Targeting acetylcholinesterase to membrane rafts: A function mediated by the proline-rich membrane anchor (PRIMA) in neurons. J. Biol. Chem. 2010, 285, 11537–11546. [CrossRef] [PubMed]

52. Dobbertin, A.; Hrabovska, A.; Dembele, K.; Camp, S.; Taylor, P.; Krejci, E.; Bernard, V. Targeting of acetylcholinesterase in neurons in vivo: A dual processing function for the proline-rich membrane anchor subunit and the attachment domain on the catalytic subunit. J. Neurosci. Off. J. Soc. Neurosci. 2009, 29, 4519–4530. [CrossRef] [PubMed]

53. Shaikh, S.; Verma, A.; Siddiqui, S.; Ahmad, S.S.; Rizvi, S.M.; Shakil, S.; Biswas, D.; Singh, D.; Siddiqui, M.H.; Shakil, S.; et al. Current acetylcholinesterase-inhibitors: A neuroinformatics perspective. CNS Neurol. Disord. Drug Targets 2014, 13, 391–401. [CrossRef] [PubMed]

54. Steinberg, B.J.; Trestman, R.; Mitropoulos, V.; Serby, M.; Silverman, J.; Coccaro, E.; Weston, S.; de Vegvar, M.; Siever, L. Depressive response to physostigmine challenge in borderline personality disorder patients. Neuropsychopharmacology 1997, 17, 264–273. [CrossRef]

55. First, M.B.; Gibbon, M.; Spitzer, R.L. User’s Guide for the Structured Clinical Interview for DSM-IV Axis II Personality Disorders: Scid-II; American Psychiatric Publishing: Arlington, VA, USA, 1997.

56. APA. Diagnostic and Statistical Manual of Mental Disorders, 4th ed.; APA: Washington, DC, USA, 1994; p. 886.

57. Tost, J.; Gut, I.G. DNA methylation analysis by pyrosequencing. Nat. Protoc. 2007, 2, 2265–2275. [CrossRef] [PubMed]

© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).